secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001808805-22-000079
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q2 net loss $14.7M; cash $334.9M; platform launch on track for mid-2024
--------------------------------------------------------------------------------

- Operating expenses of $15.5M in Q2 2022, down from $16.0M in Q1 2022.
- Net loss of $14.7M for Q2 2022 vs. $10.7M in Q2 2021; cash, equivalents & investments $334.9M.
- Platform launch (instruments and reagents) targeted for mid-2024; early access revenue starting early 2024.
- Anticipates cash runway extending well into 2025.
- Hired Eric Spence (VP Instrument Engineering) and Ken Kuhn (VP Reagent & Process Development).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000079/0001808805-22-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000079/naut-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001808805-22-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer